Real-world experience of the Lebanese haemodialysis patient infected with the hepatitis C virus and treated with direct-acting antiviral drugs

Abstract

Objective: The introduction of direct-acting antivirals (DAAs) has the potential to make a substantial contribution to HCV eradication within dialysis centers. Our study seek assess effectiveness, safety of oral DAAs, both with and without ribavirin, in the Lebanese hemodialysis population afflicted with HCV. Methods: Patient on hemodialysis infected with hepatitis C virus having either genotype 1 or 4 were treated with DAAs. We conducted an analysis of various data points, including age, gender, year of HCV diagnosis, method of infection, comorbidities, previous treatment history, fibrosis stage, current DAAs treatment. We evaluated the virological response at the end of treatment, and12 weeks after stopping treatment Results: Twenty hemodialysis patients infected with HCV genotype 1 or 4 underwent DAA treatment. The gender ratio was 0.82, with an average age of 46.2 years. The mean duration between diagnosis and treatment was 5.7 years. Half of the patients contracted the virus in dialysis centers, 5% through blood transfusion, and in 45% of cases, the cause remained unknown. Comorbidities were present in 45% of cases, with 35% been treated with Ribavirin and Pegylated Interferon. Seventy percent of patients were genotype 1 (70% 1a, 15% 1b), while 25% had fibrosis

查看原文

分享

微信好友 朋友圈 QQ好友 复制链接

本刊更多论文

黎巴嫩血液透析患者感染丙型肝炎病毒并接受直接作用抗病毒药物治疗的实际经验

目的：直接作用抗病毒药物（DAAs）的引入有可能为透析中心根除 HCV 做出重大贡献。我们的研究旨在评估口服 DAAs（含或不含利巴韦林）在黎巴嫩感染 HCV 的血液透析人群中的有效性和安全性。方法：感染了基因型 1 或 4 丙型肝炎病毒的血液透析患者接受 DAAs 治疗。我们对各种数据点进行了分析，包括年龄、性别、HCV 诊断年份、感染方式、合并症、既往治疗史、纤维化分期、当前的 DAAs 治疗。我们评估了治疗结束时和停止治疗 12 周后的病毒学应答结果：20名感染了HCV基因型1或4的血液透析患者接受了DAA治疗。性别比例为 0.82，平均年龄为 46.2 岁。从确诊到接受治疗的平均时间为 5.7 年。半数患者在透析中心感染病毒，5%的患者通过输血感染病毒，45%的患者病因不明。45%的病例存在合并症，35%的病例接受过利巴韦林和聚乙二醇干扰素治疗。70%的患者基因型为1（70%为1a，15%为1b），25%的患者纤维化程度小于F2，40%为F2-F3，20%为F4。基因型4患者接受Ombitasvir/Paritaprevir/Ritonavir +/- Ribavirin治疗，基因型1患者接受Ombitasvir/Paritaprevir/Ritonavir-Dasabuvir +/- Ribavirin治疗。12周的持续病毒学应答（SVR）率为95%，有一名患者（5%）因耐受性差在2周后中断治疗。两种基因型、不同纤维化分期或既往治疗史在治疗反应上无明显差异。结论这些研究结果代表了黎巴嫩关于血液透析患者使用 DAAs 治疗 HCV 的首个数据。研究显示，SVR12 率高达 95%，只有 5%的患者出现治疗不耐受。这些真实环境中的结果显示了血液透析中心根除 HCV 的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。